3SBio Inc (3SBio) is a fully integrated biotechnology company that carries out the research, development, manufacturing, and marketing of biopharmaceutical products. It develops products for the treatment of cancer, autoimmunity, nephrology, dermatology, and diabetes, among other diseases. The company operates through a single reporting segment, which is the development, production, marketing, and sale of biopharmaceutical products. The company’s product portfolio includes TPIAO, a recombinant human thrombopoietin (rhTPO) for the treatment of chemotherapy-induced thrombocytopenia (CIT) and immune thrombocytopenia (ITP); EPIAO, for the treatment of anemia associated with chronic kidney disease (CKD), the treatment of chemotherapy-induced anemia (CIA), and the reduction of allogeneic blood transfusion in surgery patients; Yisapu for the treatment of ankylosing spondylitis (AS) and psoriasis; Cipterbin (Inetetamab), for the treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; Mandi, generically known as minoxidil tincture for the treatment of androgenetic alopecia (AGA) and alopecia areata and Remitch, nalfuraphine hydrochloride orally disintegrating tablets for the treatment of hemodialysis pruritus.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

3SBio has established a comprehensive research and development (R&D) platform that includes four major R&D bases in Shenyang, Shanghai, Shenzhen, and Hangzhou. The company focuses on developing innovative biological products and small molecule therapeutics, covering the entire drug development process from basic research to commercialization. The R&D efforts are concentrated on oncology, autoimmune diseases, nephrology, metabolism, dermatology, and other related areas. The company has several leading biological products in various stages of clinical development and is engaged in developing monoclonal antibodies, bi-specific antibodies, fusion proteins, and small-molecule drugs. The R&D units include the Research Institution, External Cooperation Department, Clinical Department, and Registration Affair Department. The Research Institution specializes in developing biopharmaceutical products expressed in mammalian and bacterial cells and is responsible for internal pre-clinical R&D. The External Cooperation Department focuses on identifying promising chemical and pharmaceutical products and monoclonal antibody drugs for cooperative pre-clinical R&D. The Clinical Department is responsible for designing and managing clinical trials, while the Registration Affair Department handles product registration and ensures compliance with Chinese regulations. In FY2024, the company spent CNY1,326.5 million on R&D, which, as a percentage of revenue, stood at 14.6% and grew 66.9% YoY. As of December 2024, the company had 30 key product candidates within the active pipeline, out of which 29 were being developed as innovative drugs in China. The product candidates include 18 antibodies, six other biologic products, and six small-molecule drugs. It also has 13 product candidates in hematology/oncology; 11 product candidates that target autoimmune diseases, including rheumatoid arthritis (RA) and other diseases, including acute gouty arthritis, atopic dermatitis (AD), and Chronic Obstructive Pulmonary Disease (COPD); three product candidates in nephrology; two product candidates in dermatology; and one product candidate in metabolic diseases. In FY2024, the company had 68 patent applications, out of which 34 patents were granted. It also had 12 trademark applications and 14 trademarks registered.